Thor Medical – Issuance of RSU shares to members of the board
Reference is made to the stock exchange announcement made by Thor Medical ASA, the "Company") on 21 April 2024 regarding grant of restricted share units ("RSU") to the members of the board.
The Company's board of directors has today resolved to issue 1,090,974 new shares in the Company pursuant to the RSU-program. Current board members, John Andersen and Mimi Kristine Berdal, have each been issued 344,518 new shares. John Andersen has agreed to transfer all 344,518 shares to Scatec Innovation AS, where John Andersen is the CEO, a close associate of a primary insider of the Company.
Notifications of the transaction in accordance with the Market Abuse Regulation Article 19 are attached with this announcement.
Contacts
About Thor Medical ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
To learn more, visit www.thormedical.com.
Attachments
Subscribe to our company announcements
Keep up to date with our company announcements by subscribing.
Visit our pressroom and see more company announcements from us.
Our pressroom